(ANIP) ANI Pharmaceuticals - Overview
Stock: Injectables, Softgels, Cortrophin, Iluvien, Yutiq
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 33.0% |
| Relative Tail Risk | -7.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 26.32 |
| Character TTM | |
|---|---|
| Beta | 0.555 |
| Beta Downside | 0.343 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.54% |
| CAGR/Max DD | 0.87 |
Description: ANIP ANI Pharmaceuticals January 16, 2026
ANI Pharmaceuticals (NASDAQ: ANIP) is a U.S.–based biopharmaceutical firm that designs, manufactures, and markets both branded and generic injectable, oral, and topical medicines, including specialty products such as Cortrophin gel, ILUVIEN (an ophthalmic implant), and YUTIQ (a topical steroid). Its distribution network spans wholesalers, retail chains, specialty pharmacies, group purchasing organizations, hospitals, clinics, and physicians, serving domestic and international markets.
Recent data (FY 2023) show total net revenue of roughly $115 million, with ILUVIEN contributing about 30 % of that figure-a sign that ophthalmology remains a core growth engine. The U.S. generic injectable market is projected to expand at a 5-6 % CAGR through 2028, driven by cost-containment pressures in health systems, which could lift ANI’s volume-based margins if it secures additional contracts. Additionally, the company’s pipeline includes a late-stage biosimilar candidate for a high-volume biologic, a potential catalyst that could diversify revenue beyond its current specialty focus.
For a deeper, data-driven assessment of ANIP’s valuation and risk profile, you might find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 38.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.84 > 1.0 |
| NWC/Revenue: 51.74% < 20% (prev 59.66%; Δ -7.91% < -1%) |
| CFO/TA 0.12 > 3% & CFO 170.7m > Net Income 38.1m |
| Net Debt (60.0m) to EBITDA (163.6m): 0.37 < 3 |
| Current Ratio: 2.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (21.1m) vs 12m ago 8.70% < -2% |
| Gross Margin: 58.40% > 18% (prev 0.60%; Δ 5781 % > 0.5%) |
| Asset Turnover: 61.35% > 50% (prev 43.15%; Δ 18.21% > 0%) |
| Interest Coverage Ratio: 2.67 > 6 (EBITDA TTM 163.6m / Interest Expense TTM 27.1m) |
Altman Z'' 2.18
| A: 0.30 (Total Current Assets 698.4m - Total Current Liabilities 270.6m) / Total Assets 1.41b |
| B: -0.04 (Retained Earnings -50.6m / Total Assets 1.41b) |
| C: 0.05 (EBIT TTM 72.2m / Avg Total Assets 1.35b) |
| D: -0.05 (Book Value of Equity -47.8m / Total Liabilities 902.3m) |
| Altman-Z'' Score: 2.18 = BBB |
Beneish M -2.96
| DSRI: 0.86 (Receivables 252.6m/196.4m, Revenue 826.9m/555.5m) |
| GMI: 1.02 (GM 58.40% / 59.79%) |
| AQI: 0.83 (AQ_t 0.46 / AQ_t-1 0.55) |
| SGI: 1.49 (Revenue 826.9m / 555.5m) |
| TATA: -0.09 (NI 38.1m - CFO 170.7m) / TA 1.41b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of ANIP shares?
Over the past week, the price has changed by -0.01%, over one month by +5.63%, over three months by -9.30% and over the past year by +35.97%.
Is ANIP a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ANIP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.4 | 34.9% |
| Analysts Target Price | 110.4 | 34.9% |
| ValueRay Target Price | 98.9 | 20.9% |
ANIP Fundamental Data Overview February 03, 2026
P/E Forward = 9.6061
P/S = 2.2231
P/B = 3.6341
P/EG = 1.06
Revenue TTM = 826.9m USD
EBIT TTM = 72.2m USD
EBITDA TTM = 163.6m USD
Long Term Debt = 605.1m USD (from longTermDebt, last quarter)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 322.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.90b USD (1.84b + Debt 322.6m - CCE 262.6m)
Interest Coverage Ratio = 2.67 (Ebit TTM 72.2m / Interest Expense TTM 27.1m)
EV/FCF = 14.03x (Enterprise Value 1.90b / FCF TTM 135.3m)
FCF Yield = 7.13% (FCF TTM 135.3m / Enterprise Value 1.90b)
FCF Margin = 16.37% (FCF TTM 135.3m / Revenue TTM 826.9m)
Net Margin = 4.61% (Net Income TTM 38.1m / Revenue TTM 826.9m)
Gross Margin = 58.40% ((Revenue TTM 826.9m - Cost of Revenue TTM 344.0m) / Revenue TTM)
Gross Margin QoQ = 49.07% (prev 64.70%)
Tobins Q-Ratio = 1.35 (Enterprise Value 1.90b / Total Assets 1.41b)
Interest Expense / Debt = 1.47% (Interest Expense 4.73m / Debt 322.6m)
Taxrate = 21.25% (7.18m / 33.8m)
NOPAT = 56.9m (EBIT 72.2m * (1 - 21.25%))
Current Ratio = 2.58 (Total Current Assets 698.4m / Total Current Liabilities 270.6m)
Debt / Equity = 0.64 (Debt 322.6m / totalStockholderEquity, last quarter 505.8m)
Debt / EBITDA = 0.37 (Net Debt 60.0m / EBITDA 163.6m)
Debt / FCF = 0.44 (Net Debt 60.0m / FCF TTM 135.3m)
Total Stockholder Equity = 459.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.83% (Net Income 38.1m / Total Assets 1.41b)
RoE = 8.28% (Net Income TTM 38.1m / Total Stockholder Equity 459.9m)
RoCE = 6.78% (EBIT 72.2m / Capital Employed (Equity 459.9m + L.T.Debt 605.1m))
RoIC = 5.35% (NOPAT 56.9m / Invested Capital 1.06b)
WACC = 6.94% (E(1.84b)/V(2.16b) * Re(7.96%) + D(322.6m)/V(2.16b) * Rd(1.47%) * (1-Tc(0.21)))
Discount Rate = 7.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.76%
[DCF Debug] Terminal Value 75.31% ; FCFF base≈110.9m ; Y1≈72.8m ; Y5≈33.2m
Fair Price DCF = 33.05 (EV 802.4m - Net Debt 60.0m = Equity 742.3m / Shares 22.5m; r=6.94% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 6.54 | EPS CAGR: 5.71% | SUE: -3.37 | # QB: 0
Revenue Correlation: 98.39 | Revenue CAGR: 42.15% | SUE: 2.54 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.58 | Chg30d=-0.038 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=8.36 | Chg30d=-0.164 | Revisions Net=+0 | Growth EPS=+10.5% | Growth Revenue=+12.3%